Showing results 1 to 2 of 2
Phase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection.
Proceeding/Conference:55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA 29 Oct-2 Nov 2004 (Published in Hepatology)
Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV
Proceeding/Conference:Journal of Hepatology